DNA Production Protein Production 
Drug Target Review
JULY 5, 2023
A good introduction to the use of CHO cells for biotherapeutics production can be found in an article commemorating the 20th anniversary of the approval of a product produced using CHO cells. Over time, there may also be a cost benefit with developing a proprietary system if there is a pipeline of multiple products to produce.
FDA Law Blog: Biosimilars
MARCH 5, 2024
Gaulkin & Riëtte van Laack — As readers of this blog know, there is a lot of contention about the naming of alternative protein products (APPs), including both plant-based and cell-cultured alternatives for (traditional) animal products. We’ve previously blogged about this ongoing battle here , here , here , and here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sygnature Discovery
SEPTEMBER 12, 2024
Structures solved of many different protein classes, including membrane proteins, protein complexes and recently RNA. With capabilities across X-ray Crystallography Crystallisation/co-crystallisation screening of proteins, DNA, and RNA using in-house and commercial screens at various temperature.
Agency IQ
APRIL 12, 2024
Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue. How does “potency” apply to cell and gene therapy (CGT) products?
Broad Institute
AUGUST 24, 2022
Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors. "The These data suggest a multi-omics predictor for chemotherapy response is within reach.
Dark Matter Blog
JULY 16, 2021
As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. 49 years ago, when I was 16 years old, I wanted to do exactly what I am doing now. The only subject in school that held my interest was biology.
Broad Institute
JANUARY 14, 2025
The treatment, which uses base editing to make a single-letter change in DNA, reduced levels of the disease-causing prion protein in the brain by as much as 60 percent. In 2018, Liu, who works on the same floor as Minikel and Vallabh at Broad, approached them and proposed a collaboration.
Expert insights. Personalized for you.
106 
Let's personalize your content